Trial Profile
A retrospective study to investigate the efficacy of a fluocinolone acetonide implant (Retisert®) combined with an Ahmed™ glaucoma valve compared to an Ahmed valve alone in patients with uveitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jan 2016
Price :
$35
*
At a glance
- Drugs Fluocinolone acetonide (Primary)
- Indications Open-angle glaucoma; Uveitis
- Focus Therapeutic Use
- 05 Jan 2016 New trial record
- 01 Dec 2015 Primary endpoint (Surgical success), has been met according to results published in the Ophthalmology and Therapy.
- 01 Dec 2015 Results published in the Ophthalmology and Therapy